Dr. David “Doc” Eifrig is one of the few newsletter gurus whose resume holds up when you pull the thread: a decade on Wall Street including a derivatives-trading seat at Goldman Sachs, then a medical degree with clinical honors from UNC-Chapel Hill, then, since 2008, the editor of Stansberry Research’s Retirement Millionaire. His name is all over the current “Mar-a-Lago Trade” campaign, so before you let any silver-and-deadline pitch move your money, you deserve the same thing we give every guru in our track-record audit guide: the verifiable record, nothing sold, nothing sugarcoated. This dossier sits in the same evidence file as our coverage of his boss, Porter Stansberry, and our breakdown of the Mar-a-Lago Trade promo itself.

Who Doc Eifrig actually is

Start with the bio, because unlike half the “gurus” we profile, Eifrig’s checks out against sources outside his publisher’s own marketing.

Per Stansberry Research’s team page, the arc runs like this: a BA from Carleton College in Minnesota, an MBA from Northwestern’s Kellogg School (Dean’s List, double major in finance and international business), then roughly a decade trading derivatives — including at Goldman Sachs, Chase Manhattan Bank, and Yamaichi Securities, the Japanese house once nicknamed the “Goldman Sachs of Japan.” He has said he walked away from a Senior Vice President seat because he was sick of Wall Street’s greed, went through Columbia’s postbaccalaureate premedical program, and earned his MD with clinical honors from the University of North Carolina at Chapel Hill, where he was class president and was admitted to the Order of the Golden Fleece, the university’s highest honor. He completed a molecular genetics research fellowship at Duke and became a board-eligible eye surgeon.

Along the way he co-founded a small biotech company, Mirus Bio, which was sold to Roche for $125 million in 2008 — the same year he joined Stansberry Research and launched Retirement Millionaire. He’s also CEO of MarketWise, Stansberry Research’s publicly traded parent company. That last fact matters more than the resume: the man pitching you a newsletter is also an executive of the company that sells the newsletter. That’s not a disqualifier — it’s context. When the boss of the publisher is the face of the ad, the incentives line up around subscriptions, not around your particular retirement account.

The independent footprint roughly corroborates the bio: a 2019 Meb Faber podcast appearance (Episode 143, “Most People Run Losses Into the Ground”), an Amazon author page with five books, and years of coverage in Stock Gumshoe’s Retirement Millionaire archive. No stockbroker misconduct findings turn up in a routine search. For a genre where “former hedge fund manager” sometimes means “one summer at a fund of funds,” Eifrig’s credentials are unusually solid.

What he actually publishes

Eifrig’s stable at Stansberry Research includes Retirement Millionaire (launched 2008), Retirement Trader (launched April 2010, a put-selling and covered-call letter), Income Intelligence, Prosperity Investor, and the free daily Health & Wealth Bulletin. He also authored books in the “health and wealth” vein, including The Big Book of Income and retirement titles.

Retirement Millionaire itself is a oddity in the newsletter world, and it’s worth being precise about what it is. Stock Gumshoe’s review page describes it as covering “retirement issues, discounts and deals, and investment strategies and concepts — not focused solely on being an investment-picking letter,” though it does make recommendations. Gumshoe’s reader ratings — 4.1 out of 5 across 344 votes, with investment performance rated 3.9 out of 5 on 97 votes — put it among the better-regarded letters in that archive. One longtime Gumshoe commenter called it “the wisest investment newsletter of the Stansberry bunch,” noting conservative, long-term, diversified picks. Reader votes are reader votes, not an audit — but for a Stansberry-family product, that’s a notably gentle consensus.

Retirement Trader is where the actual audited-style track record lives, and it’s the source of the claim Eifrig is most known for.

The 123-winners claim, audited

Here’s the claim that made Eifrig famous inside the newsletter business: 123 consecutive closed winning positions in Retirement Trader, no closed losers since the letter launched in April 2010. Stansberry promoted it in a 2013 “Masters Series” Digest two-parter (“The S&A Digest addresses controversy about Doc Eifrig’s Retirement Trader track record”), gave him an “A+” on the annual company report card, and even carried the streak into a Fox Business appearance.

Notice the word “controversy” in Stansberry’s own headline. The publisher itself felt the need to explain the streak, because critics — including, historically, options-savvy readers — raised a fair question: how do you sell puts for years and never book a loss?

Stansberry’s own explanation is the receipt here, so let’s audit it rather than repeat it. The Digest concedes that roughly 21% of Eifrig’s put sales ended with subscribers put the stock — forced to buy shares at the strike price when the shares were trading below it. By any mark-to-market reading, those positions were underwater at the moment of assignment. Stansberry’s worked example: the March 2012 Wells Fargo May $33 put sale, where subscribers were put shares at $33 while the stock traded around $30.94 — down roughly $0.28 a share even after the $1.25 premium. The Digest’s answer is that Eifrig then recommended selling covered calls against the assigned shares (the July $33 calls at $0.86), converting the position to a 6.6% gain by July — and that this “manage the position after assignment” method is why the streak counts no losses.

So the honest audit reads: the “123 consecutive winners” is real as Stansberry scores it, but the scoring rule does the heavy lifting. A win means the trade eventually closed positive after follow-on call-selling, dividends, and premiums — not that every entry printed money. The same Digest series shows the streak’s own author conceding it “can’t last forever.” If you evaluate Eifrig’s options work the way a risk manager would — mark the position when assigned, count collateral tied up, count opportunity cost — the record is very good for the genre, but “never loses” is a marketing construction, not a law of nature. Our track-record audit guide covers this pattern generally: always ask how the house scores a “win” before you let a streak sell you anything.

How the Retirement Millionaire pitches are built

Eifrig’s editorial letters lean conservative, but the marketing that surrounds him is classic Stansberry machinery, and you should know the pattern. Stock Gumshoe’s Retirement Millionaire archive is a long shelf of teasers following the same three-beat structure:

  1. The fear hook. A macro collapse scenario with Eifrig’s Goldman pedigree stapled to it — e.g., the teaser Gumshoe catalogued as “Former Goldman Sachs Exec Who Predicted 2022 Crash Warns of Huge Event in 2025.” (Whether the 2022 call was as clean as the ad implies is exactly the kind of claim our audit guide teaches you to check.)
  2. The manufactured deadline. A dated event the pitch says you must position for before — that’s the engine of the current “Mar-a-Lago Trade” campaign and its September 15 date, not a fact about the market.
  3. The safe-income landing. After the fright, the actual product is presented as the conservative shelter — dividend payers, gold and silver plays, “safe” income picks that flatter the reader’s caution back at them.

Notice the shape: the fear is loud, the pick is quiet. That gap between the ad and the letter is the whole reason we keep promo literacy on the shelf. The letter inside the wrapper and the ad on the outside are two different products made by two different incentives.

How his past calls aged

A few verifiable markers, without cherry-picking either direction:

  • The options letters’ streak — genuinely strong in its own scoring terms, and even marked honestly, selling puts on blue chips like Wells Fargo, Intel, Johnson & Johnson, and Abbott in 2011–2012 was a profitable strategy during a rising market. The same strategy in a 2008-style gap would produce real drawdowns; the streak is partly the strategy and partly the era.
  • The “predicted the 2022 crash” framing — a marketing retro-fit of the kind every publisher does. Eifrig was plainly cautious on valuations into 2022 (as were many), but the ad converts “was bearish and then the market fell” into prophecy. Treat it as a resume item, not a forecast tool.
  • The Mar-a-Lago Accord pivot — his current campaign thesis, a “monetary reset for the dollar” narrative that MarketWise’s own explainer frames around a deliberately weakening dollar and hard assets. It’s a market thesis with real intellectual company (the phrase has circulated in macro commentary since early 2025), recycled through the promo funnel with gold and silver as the fear-hedge landing. Whether it pays off is a forecast we don’t grade — how it’s marketed is what we cover, in the Mar-a-Lago Trade breakdown.

The bottom line on the record

Is Doc Eifrig legit? On the verifiable evidence: yes — the credentials are real, the career arc is real, the letters exist and have run for well over a decade, and his options track record is among the strongest in the genre even after you discount the house scoring. He is not a hype-merchant in the vein of the worst operators in this industry, and the independent reader sentiment around his letters is respectful.

But legit is not the same as worth buying today, and a strong 2010–2013 options streak is not a reason to act on a September 15 deadline. The man is also CEO of the company selling you the subscription — that’s the receipt to keep in your pocket. Read the promo with the same eyes you’d read any Stansberry campaign, know your cancellation rights before you ever hand over a card number, and never let a deadline manufactured by a marketing department make an investment decision for you.

No pick is decoded here, no ticker revealed, and nothing in this dossier is a buy or sell recommendation. Flak Jacket Finance is independent third-party coverage — we hold no position in any product mentioned and we don’t sell subscriptions.